Macrolides: Pharmacokinetics and pharmacodynamics

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 17-23

  Van Bambeke, F ^a   Tulkens, P M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Azithromycin; Clinical efficacy; Macrolides; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; LACTAM; MACROLIDE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIUM; DOSE RESPONSE; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; KINETICS; LACTAMS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 0002587039     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00406-x     Document Type: Article

References (42)

1. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995;7(Suppl. 2):47-52.
2. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43:1003-112.
3. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Cefepime: a new fourth-generation cephalosporin. Am J Hosp Pharm 1994;51:463-77.
4. Jacolot A, Incagnoli P, Edouard AR, et al. Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1999;25:486-91.
5. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998;77(Suppl. 6):7-12.
6. Schentag JJ, Birmingham MC, Paladino JA, et al. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect 1997;12:278-93.
7. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999;11:426-39.
8. Modai J. High-dose intravenous fluoroquinolones in the treatment of severe infections. J Chemother 1999;11:478-85.
9. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999;17:365-87.
10. Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996;38(Suppl. A):141-54.
11. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996;30:1029-31.
12. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997;9(Suppl. 1):64-73.
13. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-60.
14. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother 1999;11:11-27.
15. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
16. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob Agents Chemother 1999;43:1242-51.
17. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997;16:438-43.
18. Craig WA. The postantibiotic effect. Clin Microbiol News 1991;13:121-4.
19. Horgen L, Legrand E, Rastogi N. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. Res Microbiol 1997;148:673-81.
20. Li RC, Lee SW, Kong CH. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. J Antimicrob Chemother 1997;40:39-45.
21. Aeschlimann JR, Hershberger E, Rybak MJ. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1914-8.
22. Boswell FJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999;43(Suppl. B):43-9.
23. Cars O, Odenholt-Tornqvist I. The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993;31:159-66.
24. McDonald PJ, Weterhall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leucokytes. Rev Infect Dis 1981;3:38-44.
25. Pruul H, McDonald PJ. Lomefloxacin-induced modification of the kinetics of growth of Gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils. J Antimicrob Chemother 1990;25:91-101.
26. Delogu G, Iona E, Amati F, et al. "Killing" of Pseudomonas aeruginosa isolated from patients with critical post-operative complications. Effects of various antibiotics. Ann Ital Chir 1997;68:219-24.
27. Ramadan MA, Tawfik AF, Shibl AM, Gemmell CG. Post-antibiotic effects of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. J Med Microbiol 1995;42:362-6.
28. Gudmundsson A, Gottfredsson M, Erlendstottir H, Gudmundsson S. Impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob Agents Chemother 1991;35:2617-24.
29. Horgen L, Jerome A, Rastogi N. Pulsed-exposure and postantibiotic leukocycte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. Antimicrob Agents Chemother 1998;42:3006-8.
30. Gudmundsson S, Einarsson S, Erlendsdottir H, Moffat J, Bayer W, Craig WA. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother 1993;31(Suppl. D):177-91.
31. Hof H. Intracellular microorganisms: a particular problem for chemotherapy. Introduction. Infection 1991;19(Suppl. 4):S193-4.
32. Scorneaux B, Ouadrhiri Y, Anzalone G, Tulkens PM. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother 1996;40:1225-30.
33. van den Broek PJ. Activity of antibiotics against microorganisms ingested by mononuclear phagocytes. Eur J Clin Microbiol Infect Dis 1991;10:114-8.
34. Düzgunes N, Perumal VK, Kesavalu L, Goldstein JA, Debs RJ, Gangadharam PRJ. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium - M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother 1988;32:1404-11.
35. Garcia-Rodriguez JA, Garcia Sanchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 1991;35:756-9.
36. Smith RP, Baltch AL, Franke MA, Michelsen PB, Bopp LH. Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 2000;45:483-8.
37. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996;25:213-7.
38. Wenisch C. Pharmacokinetic effects of antibiotics on the development of bacterial resistance particularly in reference to azithromycin. Wien Med Wochenschr 2000;150:37-41.
39. Craig WA. The future - can we learn from the past? Diagn Microbiol Infect Dis 1997;27:49-53.
40. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999;115(Suppl. 3):19S-23S.
41. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3-or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999;43:163-5.
42. Van Bambeke F, Gerbaux C, Michot JM, d'Yvoire MB, Montenez JP, Tulkens PM. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J Antimicrob Chemother 1998;42:761-7.